Loading
Cancer Survivorship and Care · Journal article
Lasers in Medical Science · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This scoping review synthesizes evidence on vaginal CO₂ laser therapy for genitourinary syndrome of menopause in breast cancer survivors. Most observational studies reported within-group improvements, but the two sham-controlled randomized trials did not demonstrate clinically meaningful benefit over sham treatment, and the evidence base remains heterogeneous, underpowered, and limited to short-term follow-up.
Scoping review in accordance with PRISMA-ScR guidelines. Studies enrolling breast cancer survivors (current or previous) with genitourinary syndrome of menopause treated with vaginal CO₂ laser therapy. Intervention: Vaginal fractional CO₂ laser therapy. Compared with: Sham treatment, radiofrequency, or promestriene in subset of trials.
22 study reports representing approximately 1,099 BCS participant observations included Most observational studies reported within-group improvements in GSM symptoms, FSFI, VAS, and Vaginal Health Index scores Two sham-controlled randomized trials did not demonstrate a clinically meaningful benefit over sham treatment
Long-term safety and efficacy data not available; only short-term tolerability established
Clinicians should recognize that while vaginal CO₂ laser therapy appears tolerated short-term in breast cancer survivors with GSM, current evidence does not support its efficacy over sham treatment. Further adequately powered sham-controlled trials with standardized outcomes and long-term follow-up are needed before recommending this therapy as an alternative to hormonal options.
A scoping review of heterogeneous observational studies and small RCTs showing short-term tolerability but no clinically meaningful benefit over sham; evidence is too limited and inconsistent to guide practice.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that while vaginal CO₂ laser therapy appears tolerated short-term in breast cancer survivors with GSM, current evidence does not support its efficacy over sham treatment. Further adequately powered sham-controlled trials with standardized outcomes and long-term follow-up are needed before recommending this therapy as an alternative to hormonal options.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Genitourinary syndrome of menopause (GSM) is highly prevalent among breast cancer survivors (BCSs), largely due to treatment-induced hypoestrogenism. Hormonal therapies are often contraindicated, creating a need for non-hormonal options. This scoping review aimed to map and critically summarize the evidence on the efficacy and safety of vaginal CO₂ laser therapy for GSM in women with current or previous breast cancer. A scoping review was conducted in accordance with PRISMA-ScR guidelines. PubMed, Embase, Cochrane Library, Web of Science, and APA PsycInfo were searched from inception to June 2025. Randomized controlled trials and observational studies investigating vaginal CO₂ laser therapy for GSM among BCSs were included. Data were extracted on study design, laser protocols, outcomes, follow-up, and adverse events. Twenty-two study reports representing approximately 1,099 BCSs participant observations were included. Most observational studies reported within-group improvements in GSM symptoms, FSFI, VAS, and Vaginal Health Index scores. Treatment was generally well tolerated in the short term. However, study designs, populations, outcome measures, and follow-up durations were heterogeneous. The two sham-controlled randomized trials did not demonstrate a clinically meaningful benefit over sham treatment, whereas the two active-comparator randomized trials found no clear differences between CO₂ laser therapy, radiofrequency, and promestriene. Vaginal CO₂ laser therapy appears well tolerated in the short term, but current evidence remains limited. Further adequately powered sham-controlled trials with standardized outcomes and long-term follow-up are needed to establish treatment-specific efficacy and safety in BCSs with GSM.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.